MSH2 and colorectal carcinoma: In a cohort of 41 LS families, EpCAM deletion carriers had a cumulative CRC risk of 75% by age 70, which was higher than that of MSH6 carriers (50%) and similar to that of MSH2 (77%) and MLH1 mutation carriers (79%) (Kempers et al., 2011).